| Literature DB >> 35530631 |
Sanjay Kumar1, Anchita Diwan1, Parinita Singh1, Shikha Gulati1, Devanshu Choudhary1, Ayush Mongia1, Shefali Shukla1, Akanksha Gupta1.
Abstract
Surface-modified gold nanoparticles are recognized as promising gene delivery vehicles in the treatment of cancer owing to their excellent biocompatibility with biomolecules (like DNA or RNA) and their unique optical and structural properties. In this context, this review article focuses on the diverse transfection abilities of the gene to the targeted cell on the basis of different shapes and sizes of gold nanoparticles in order to promote its effective expression for cancer treatment. In addition, recent trends in gold nanoparticle mediated gene silencing, gene delivery, detection and combinatory therapies are highlighted considering their cytotoxic effects on healthy human cells. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35530631 PMCID: PMC9069781 DOI: 10.1039/c9ra03608c
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Surface modified gold nanoparticles as gene delivery vehicles to produce gene silencing effect
| S. No. | Type of gold nanoparticles (shape & size) | Type of cancer treated/targeted cells | Delivery vehicle | Targeted Functions | Reference |
|---|---|---|---|---|---|
| 1 | Gold nanoparticles (∼50 nm) | Breast cancer | AuNP-PEI/eEF-2K siRNA | Gene knockdown |
|
| 2 | Gold nanorods (∼70 nm × ∼30 nm) | HepG2 cancer cells | PEI-Au/siRNA and PEI-Au/siRNA@ZGOC | Protection of SiRNA for gene silencing and LDDS gene vector system of PEI-Au/siRNA@ZGOC which binds siRNA for gene silencing |
|
| 3 | Gold nanoparticles (∼50 nm) | Gastric cancer | HAG5PAMAMAuMETase | Suppressed the growth of tumor |
|
| 4 | Gold nanoparticles (65–128 nm) | Breast (MCF-7), and cervical (KB) cells | Au : G5D and Au : G5D : FA NPs | Affords good protection to the pDNA against nucleases |
|
| 5 | Gold nanostars (72.5 ± 3.2 nm) | Hepatocellular carcinoma cells (HepG2) and SGC7901 cells | siRNA/9R/DG-AuNS (hydrazone) | Gene silencing and inhibiting the cell growth rate |
|
| 6 | Gold nanoclusters (2.6 ± 0.5 nm) | Panc-1 | AuNC-siRNA | Suppressed pancreatic tumour progression |
|
| 7 | Gold nanostars (AuNS TRITON: 80–90 nm; AuNS LSB: 50–70 nm; shrunk AuNS LSB: 20–30 nm) | MCF-7/Luc cells | AuNS-POLYMER-siRNA | Suppressed luciferase expression |
|
| 8 | Gold nanoshells (159 ± 11 nm) | Triple-negative breast cancer | LbL-NS | Suppressed cancer cell growth |
|
| 9 | Gold nanorods (48 × 16 nm) | Ovarian cancer cell line (SKOV-3) | DTC-anchored siRNA duplex | Efficient knockdown |
|
| 10 | Gold nanoassembly (20–25 nm) | HeLa cells | Rf, RfSH and Rf@AuNPs | DNA damage and apoptosis |
|
| 11 | Gold nanoparticles (30.42 ± 0.29 nm) | MCF-7 and MDA-MB-453 cells | AuNP@PEG@anti-RAB27A | Gene silencing and decrease of exosome release |
|
| 12 | Gold nanoparticles (∼6 nm) | A375 human melanoma cells | AuNP-SX/SS/SN-DNA and AuNP-TSX/TSS/TSN-plasmid complexes | To modify cellular protein expression |
|
| 13 | Gold nanocages (∼50 nm) | Hepatocellular carcinoma (HCC) | HA/anti-miR-21/PPAuNCs | Reversing MDR (multidrug resistance) |
|
| 14 | Gold nanoclusters (103.7 ± 3.8 nm) | A375 cells | TAT-AuNS/Cas9 protein/sgRNA | Inhibited the tumour growth |
|
| 15 | Gold nanoparticles (5.3 nm) | Lung cancer, breast cancer, pancreas cancer, skin cancer, ovary cancer | TDDS (Au-TR-DX-si) | Knockdown of erbB2 oncogene |
|
| 16 | Gold nanoparticles (65–128 nm) | HEK293, HepG2, Caco-2, MCF-7, KB | Au : G5D, Au : G5D : FA, G5D, G5D : FA | Apoptosis, enhanced transfection efficiency |
|
Fig. 1Gene silencing on targeted cancer cell site using white LED light (∼700 nm emission). Gold nanorods-assembled ZnGa2O4–Cr nanofibers for LED-amplified gene silencing.[39]
Fig. 2Schematic illustration for modification of AuNPs via polyethyleneimine.[33]
Characterization of AuNPs for enhanced gene delivery
| S. no. | Type of gold nanoparticles (shape & size) | Type of cancer treated | Delivery vehicle | Targeted functions | Reference |
|---|---|---|---|---|---|
| 1 | Gold nanorods (∼30 nm × 10 nm) | HEK293, HepG2 cells | AHP, sm-AHP, CD-PGEA | Apoptosis, enhanced transfection efficiency |
|
| 2 | Gold nanoparticles (2.9 nm and 3.1 nm) | EGFP, Luc cells | Au DENPs-mPEG and Au DENPs-PEG-FA | Low immunogenicity and enhanced gene transfection efficiency |
|
Fig. 3Schematic representation for miRNA detection using AuNP – 2′-OMe-DNA probes.[57]
Detection and imaging of tumor cells via modified gold nanoparticles
| S. no. | Type of gold nanoparticles (shape & size) | Type of cancer treated | Delivery vehicle | Inference | Reference |
|---|---|---|---|---|---|
| 1 | Gold nanoparticles (L25, L50, L100, L200) | HeLa cells | PEG-Au PENPs | L25 has high cellular uptake |
|
| 2 | Gold nanoparticles (199.4 ± 25.2 nm) | MCF-7, HepG2 and HEK293 cells | Au-CS-PLGA NPs and FA-Au-CSPLGA NPs | High cellular uptake |
|
| 3 | Gold nanosphere (∼13 and 50 nm), star (∼40 nm) | U87 cells | siRNA | High cellular uptake |
|
| 4 | Gold nanoparticles (∼10 nm) | MCF-7, A549 cells | GDD, GF | Enhanced cellular uptake |
|
Fig. 4Depiction of targeted gene delivery of GF/DNA (i) in vitro and (ii) in vivo.[121]
Fig. 5Schematic illustration of PEI-Au/siRNA onto ZGOC nanofibers.[39]
Fig. 6Combinatory therapy representing schematic illustration of SPR sensing system for detecting miRNA.[139]
Various other combinatory characteristic features of gold nanoparticles
| S. No. | Type of gold nanoparticles (shape & size) | Type of cancer treated/targeted cells | Delivery vehicle | Targeted Functions | Reference |
|---|---|---|---|---|---|
| 1 | Gold nanoparticles (13 nm ± 2 nm) | Breast cancer | AuNP-2′-OMe-DNA probes | miRNA-21 detection and inhibition leading to apoptotic cells death |
|
| 2 | Gold nanoplates | HCV genomic human hepatocarcinoma | TAT/FDz-pAuNPs | To investigate the synergistic effect of NIR irradiation with pAuNPs-based chemotherapy |
|
| 3 | Gold nanobeacon (∼13 nm) | Colorectal carcinoma | Thiol-DNA-hairpin Cy3 sequences: antisense gold nanobeacon: nonsense gold nanobeacon | To detect and inhibit KRAS gene for a theranostic approach in colorectal carcinoma cells |
|